Skip to main content
SURMODICS INC logo

SURMODICS INC — Investor Relations & Filings

Ticker · SRDX ISIN · US8688731004 LEI · 549300H76KXCAAGUS878 US Manufacturing
Open in API
Filings indexed 1,062 across all filing types
Latest filing 2012-09-10 Major Shareholding Noti…
Country US United States of America
Listing US SRDX

About SURMODICS INC

https://www.surmodics.com/

Surmodics, Inc. provides performance-enhancing technologies for the healthcare industry, focusing on medical devices and in vitro diagnostics. The company is a leading provider of surface modification technologies, offering customized hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. In addition to its coatings business, Surmodics develops and commercializes a portfolio of vascular intervention medical devices for the treatment of peripheral arterial and venous disease, including thrombectomy and radial access platforms. The company also offers end-to-end contract development and manufacturing services. Its In Vitro Diagnostics (IVD) division supplies critical chemical components for immunoassays and microarrays, aiming to enhance the sensitivity and reproducibility of diagnostic tests.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 7 TO THE SCHEDULE 13D
Major Shareholding Notification
2012-09-10 English
SC TO-I/A Filing
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 3 to Schedule TO, which is a Tender Offer Statement filed under the Securities Exchange Act of 1934. It relates to a tender offer by SurModics, Inc. to purchase shares of its common stock. The document includes details about the tender offer, filing fee calculation, and references to previous amendments and the original Schedule TO filing. It is a regulatory filing related to a tender offer, not a full report or financial statement. The Schedule TO and its amendments are filings that provide information about tender offers but are not themselves merger proxy statements or merger communications (which would be classified under MA or TAR). Given the nature of the document as an SEC tender offer statement amendment, the appropriate classification is Regulatory Filings (RNS). The document length is 4647 characters, which is not extremely short, and it contains substantive information about the tender offer amendment, so it is not a mere announcement. Therefore, the best fit is RNS with high confidence.
2012-09-06 English
AMENDMENT NO. 6 TO THE SCHEDULE 13D
Major Shareholding Notification
2012-08-27 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 27, 2012. It reports the termination of a material definitive agreement and the resignation of a board member, Jeffrey C. Smith, with no disagreement stated. The document includes a press release announcing the resignation. The key content relates to changes in the company's board of directors. There are no financial statements or detailed financial data presented. The primary focus is on management changes, specifically a director's resignation. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3216 characters, which is relatively short but contains substantive information about management changes, not just an announcement of a report or a certification. Hence, it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2012-08-27 English
SC TO-I/A Filing
M&A Activity Classification · 100% confidence The document is an Amendment No. 2 to Schedule TO, which is a Tender Offer Statement filed under the Securities Exchange Act of 1934. It relates to a tender offer by SurModics, Inc. to purchase shares of its common stock. The document amends and supplements previous filings related to the tender offer, including references to Schedule 13D ownership disclosures and director resignations. The Schedule TO and its amendments are filings specifically related to tender offers and takeover bids, which fall under the category of M&A Activity. The document is not a full annual or quarterly report, audit report, or earnings release, nor is it a proxy statement or voting results announcement. It is a regulatory filing related to a tender offer transaction, which matches the M&A Activity category. The document length and content confirm it is a substantive filing, not just an announcement or certification. Therefore, the correct classification is M&A Activity (TAR).
2012-08-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-08-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.